An open-label trial of risperidone augmentation for refractory anxiety disorders

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 381-385

  Simon, Naomi M ^a,b   Hoge, Elizabeth A ^a,b   Fischmann, Diana ^a,b   Worthington III, John J ^a,b   Christian, Kelly M ^a,b   Kinrys, Gustavo ^b,c   Pollack, Mark H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CAMBRIDGE HEALTH ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INCREASED APPETITE; MALE; MUSCLE CRAMP; NAUSEA; OPEN STUDY; PANIC; PRIORITY JOURNAL; REFRACTORY PERIOD; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; STRUCTURED INTERVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY URGENCY; URINE INCONTINENCE; VIVID DREAM; WEIGHT GAIN; XEROSTOMIA;

EID: 33645774689     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0307     Document Type: Article

References (33)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60(suppl 22):29-34
3. Keller MB. Raising the expectations of long-term treatment strategies in anxiety disorders. Psychopharmacol Bull 2002;36(suppl 2):166-174
4. Ballenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry 1999;46:1579-1594
5. Yonkers KA, Bruce SE, Dyck IR, et al. Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety 2003;17:173-179
6. Pollack MH. Unmet needs in the treatment of anxiety disorders. Psychopharmacol Bull 2004;38:31-37
7. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425
8. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801
9. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
10. Eidelman I, Seedat S, Stein DJ. Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety 2000;11:187-188
11. Krashin D, Oates EW. Risperidone as an adjunct therapy for posttraumatic stress disorder. Mil Med 1999;164:605-606
12. Monnelly EP, Ciraulo DA. Risperidone effects on irritable aggression in posttraumatic stress disorder [letter]. J Clin Psychopharmacol 1999;19:377-378
13. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005;57:474-479
14. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Version (SCID-I/P, Version 2.0). New York, NY: New York State Psychiatric Institute, Biometrics Research: 1994
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
16. Mennin DS, Fresco DM, Heimberg RG, et al. Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J Anxiety Disord 2002;16:661-673
17. Pollack MH. Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003;17:276-282
18. Reiss S. Peterson R, Gursky M, et al. Anxiety sensitivity, anxiety frequency, and the prediction of fearfulness. Behav Res Ther 1986;24:1-8
19. Rapaport MH, Davidson JR. The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. Psychopharmacol Bull 1998;34:167-168
20. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95
21. Shear MK, Rucci P, Williams J, et al. Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res 2001;35:293-296
22. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
24. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1777-1779
25. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002;16:365-368
26. Hamner MB, Deitsch SE. Brodrick PS, et al. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003;23:15-20
27. Worthington JJ III, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11
28. Jolley D. Clinical experience with thioridazine (Melleril) in the treatment of anxiety and depression associated with emotional disorders in general practice. Curr Ther Res Clin Exp 1971;13:111-128
29. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986;47:170-174
30. Carson WH, Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull 2004;38:38-45
31. Overstreet DH, Knapp DJ, Moy SS, et al. A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl) 2003;167:344-352
32. Citrome L. Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus. Int J Neuropsychopharmacol 2005:1-5
33. Zhang XY, Zhou DF, Cao LY, et al. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology (Berl) 2005;178:35-40